Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer

Nicole M. Myer; Kohei Shitara; Hyun C. Chung; Florian Lordick; Ronan J. Kelly; Zsolt Szabo; Z. Alexander Cao; Stephen Leong; David H. Ilson; Wilko Weichert

doi:10.1007/s00432-021-03902-1

Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer

Nicole M. Myer, Kohei Shitara, Hyun C. Chung, Florian Lordick, Ronan J. Kelly, Zsolt Szabo, Z. Alexander Cao, Stephen Leong, David H. Ilson, Wilko Weichert

Department of Internal Medicine

Research output: Contribution to journal › Review article › peer-review

2 Citations (Scopus)

Abstract

Despite new therapeutic options, advanced gastric cancer remains associated with a poor prognosis compared with other cancers. Recent gains in the treatment of gastric cancer were accompanied by the identification of novel biomarkers associated with various cellular pathways and corresponding diagnostic technologies. It is expected that the standardization of clinical workflow and technological refinements in biomarker assessment will support greater personalization and further improve treatment outcomes. In this article, we review the current state of prognostic and predictive biomarkers in gastric cancer.

Original language	English
Pages (from-to)	2023-2043
Number of pages	21
Journal	Journal of cancer research and clinical oncology
Volume	148
Issue number	8
DOIs	https://doi.org/10.1007/s00432-021-03902-1
Publication status	Published - 2022 Aug

Bibliographical note

Funding Information:
Funding for this study was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Medical writing and/or editorial assistance was provided by Dominic Singson, MD, and Holly C. Cappelli, PhD, CMPP, of ApotheCom (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Publisher Copyright:
© 2022, Merck & Co., Inc., Kenilworth, NJ, USA and its affiliates under exclusive license to Springer-Verlag GmbH Germany, part of Springer Nature.

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00432-021-03902-1

Cite this

@article{ad626d051da04d4083f836fea25417a7,

title = "Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer",

abstract = "Despite new therapeutic options, advanced gastric cancer remains associated with a poor prognosis compared with other cancers. Recent gains in the treatment of gastric cancer were accompanied by the identification of novel biomarkers associated with various cellular pathways and corresponding diagnostic technologies. It is expected that the standardization of clinical workflow and technological refinements in biomarker assessment will support greater personalization and further improve treatment outcomes. In this article, we review the current state of prognostic and predictive biomarkers in gastric cancer.",

author = "Myer, {Nicole M.} and Kohei Shitara and Chung, {Hyun C.} and Florian Lordick and Kelly, {Ronan J.} and Zsolt Szabo and Cao, {Z. Alexander} and Stephen Leong and Ilson, {David H.} and Wilko Weichert",

note = "Funding Information: Funding for this study was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Medical writing and/or editorial assistance was provided by Dominic Singson, MD, and Holly C. Cappelli, PhD, CMPP, of ApotheCom (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Publisher Copyright: {\textcopyright} 2022, Merck & Co., Inc., Kenilworth, NJ, USA and its affiliates under exclusive license to Springer-Verlag GmbH Germany, part of Springer Nature.",

year = "2022",

month = aug,

doi = "10.1007/s00432-021-03902-1",

language = "English",

volume = "148",

pages = "2023--2043",

journal = "Journal of Cancer Research and Clinical Oncology",

issn = "0171-5216",

publisher = "Springer Verlag",

number = "8",

}

TY - JOUR

T1 - Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer

AU - Myer, Nicole M.

AU - Shitara, Kohei

AU - Chung, Hyun C.

AU - Lordick, Florian

AU - Kelly, Ronan J.

AU - Szabo, Zsolt

AU - Cao, Z. Alexander

AU - Leong, Stephen

AU - Ilson, David H.

AU - Weichert, Wilko

N1 - Funding Information: Funding for this study was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Medical writing and/or editorial assistance was provided by Dominic Singson, MD, and Holly C. Cappelli, PhD, CMPP, of ApotheCom (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Publisher Copyright: © 2022, Merck & Co., Inc., Kenilworth, NJ, USA and its affiliates under exclusive license to Springer-Verlag GmbH Germany, part of Springer Nature.

PY - 2022/8

Y1 - 2022/8

N2 - Despite new therapeutic options, advanced gastric cancer remains associated with a poor prognosis compared with other cancers. Recent gains in the treatment of gastric cancer were accompanied by the identification of novel biomarkers associated with various cellular pathways and corresponding diagnostic technologies. It is expected that the standardization of clinical workflow and technological refinements in biomarker assessment will support greater personalization and further improve treatment outcomes. In this article, we review the current state of prognostic and predictive biomarkers in gastric cancer.

AB - Despite new therapeutic options, advanced gastric cancer remains associated with a poor prognosis compared with other cancers. Recent gains in the treatment of gastric cancer were accompanied by the identification of novel biomarkers associated with various cellular pathways and corresponding diagnostic technologies. It is expected that the standardization of clinical workflow and technological refinements in biomarker assessment will support greater personalization and further improve treatment outcomes. In this article, we review the current state of prognostic and predictive biomarkers in gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=85130193223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85130193223&partnerID=8YFLogxK

U2 - 10.1007/s00432-021-03902-1

DO - 10.1007/s00432-021-03902-1

M3 - Review article

C2 - 35551464

AN - SCOPUS:85130193223

SN - 0171-5216

VL - 148

SP - 2023

EP - 2043

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

IS - 8

ER -

Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this